JP2002506034A5 - - Google Patents

Download PDF

Info

Publication number
JP2002506034A5
JP2002506034A5 JP2000535346A JP2000535346A JP2002506034A5 JP 2002506034 A5 JP2002506034 A5 JP 2002506034A5 JP 2000535346 A JP2000535346 A JP 2000535346A JP 2000535346 A JP2000535346 A JP 2000535346A JP 2002506034 A5 JP2002506034 A5 JP 2002506034A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000535346A
Other versions
JP2002506034A (ja
JP3877961B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1999/001496 external-priority patent/WO1999045931A1/en
Publication of JP2002506034A publication Critical patent/JP2002506034A/ja
Publication of JP2002506034A5 publication Critical patent/JP2002506034A5/ja
Application granted granted Critical
Publication of JP3877961B2 publication Critical patent/JP3877961B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000535346A 1998-03-11 1999-03-10 Ｃｎｓ疾患の治療におけるエピアロプレグナノロン Expired - Fee Related JP3877961B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3786998A 1998-03-11 1998-03-11
US09/037,869 1998-03-11
PCT/EP1999/001496 WO1999045931A1 (en) 1998-03-11 1999-03-10 Epiallopregnanolone in the treatment of cns disorders

Publications (3)

Publication Number Publication Date
JP2002506034A JP2002506034A (ja) 2002-02-26
JP2002506034A5 true JP2002506034A5 (ja) 2005-11-17
JP3877961B2 JP3877961B2 (ja) 2007-02-07

Family

ID=21896803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000535346A Expired - Fee Related JP3877961B2 (ja) 1998-03-11 1999-03-10 Ｃｎｓ疾患の治療におけるエピアロプレグナノロン

Country Status (9)

Country Link
US (1) US6455516B1 (ja)
EP (1) EP1063999B1 (ja)
JP (1) JP3877961B2 (ja)
CN (1) CN1270718C (ja)
AT (1) ATE307592T1 (ja)
AU (1) AU756001B2 (ja)
CA (1) CA2321728C (ja)
DE (1) DE69927960T2 (ja)
WO (1) WO1999045931A1 (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
BRPI0518359A2 (pt) 2004-11-18 2008-11-18 Umecrine Ab antagonistas de gaba-esteràide e seu uso para tratamento de distérbios do snc
DE102006003508A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Arzneimittel umfassend eine Hormonkombination
DE102006003509A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Kontrazeptivum
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
DK2792681T3 (en) 2006-11-21 2017-01-23 Umecrine Ab Use of Pregnancy and Androstan Steroids in the Preparation of a Pharmaceutical Composition for the Treatment of CNS Disorders.
US8969329B2 (en) 2007-06-11 2015-03-03 University Of Southern California Allopregnanolone in a method for enhancing neurological function
US20100204192A1 (en) 2007-06-11 2010-08-12 University Of Sourthern California Agents, compositions and methods for enhancing neurological function
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US20120322781A1 (en) 2010-01-14 2012-12-20 Umecrine Mood Ab Pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
JP2014515361A (ja) 2011-05-20 2014-06-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｃｂ１受容体のアンタゴニスト
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
IL304912A (en) 2012-08-21 2023-10-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
BR112015012194B8 (pt) 2012-11-28 2022-11-22 Univ Bordeaux Derivados éter-benzil-3-(4'-substituídos) de pregnenolona
EP2925327B1 (en) * 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
MX2016008851A (es) 2014-01-29 2017-03-23 Umecrine Cognition Ab Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica.
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
SI3224269T1 (sl) * 2014-11-27 2020-10-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
WO2018127601A1 (en) * 2017-01-09 2018-07-12 Asarina Pharma Ab Injectable suspensions
KR102478510B1 (ko) * 2017-02-10 2022-12-16 아사리나 파마 아베 의학적 치료에서 사용하기 위한 3-베타-히드록시-5-알파-프레그난-20-온
EP3579842A4 (en) 2017-02-10 2020-12-23 Asarina Pharma AB 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN THE TREATMENT OF ESSENTIAL TREMMENTS
WO2019075362A1 (en) * 2017-10-12 2019-04-18 Sage Therapeutics, Inc. METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS
WO2019193138A1 (en) 2018-04-05 2019-10-10 Asarina Pharma Aps Gaba-a antagonists for treating substance withdrawal disorders
WO2023040851A1 (zh) 2021-09-14 2023-03-23 南京迈诺威医药科技有限公司 一种水溶性别孕烷醇酮衍生物及其制备方法和用途
EP4430056A1 (en) 2021-11-10 2024-09-18 Umecrine AB 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
EP4429669A1 (en) 2021-11-10 2024-09-18 Umecrine AB Steroid as a modulator of gabaa receptor
CN118251403A (zh) 2021-11-10 2024-06-25 梅克芳股份公司 用于调节GABA-A受体的α-3亚型的3.α.取代的3.β.-羟基17-肟化的雄甾烷化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
KR100394548B1 (ko) * 1994-11-23 2004-02-05 퍼듀 파머 리미티드 Gaba수용체의알로스테릭조절을위한안드로스탄및프레그난계열화합물
AU739146B2 (en) * 1997-05-02 2001-10-04 Wyeth Pregnan-3-ol-20-ones

Similar Documents

Publication Publication Date Title
BE2013C020I2 (ja)
BE2013C015I2 (ja)
BE2013C001I2 (ja)
BE2012C036I2 (ja)
BE2011C004I2 (ja)
BE2010C011I2 (ja)
BE2008C046I2 (ja)
BE1025464I2 (ja)
JP2002529157A5 (ja)
JP2002536695A5 (ja)
BRPI0017527B8 (ja)
BE2008C047I2 (ja)
JP2002526290A5 (ja)
JP2002506034A5 (ja)
IN192012B (ja)
JP2002532924A5 (ja)
JP2002506774A5 (ja)
JP2002534667A5 (ja)
JP2002518404A5 (ja)
JP2000113644A5 (ja)
ECSDI990560S (ja)
IN186270B (ja)
CN3099353S (ja)
CN3097870S (ja)
CN3099822S (ja)